EVOGENIX AIMS FOR FASTER ROAD TO REVENUE

Antibody drug company EvoGenix has opened its $9 million initial public offer ahead of plans to list on the stock exchange next month. Boasting a technology designed to identify and refine new antibody drugs, the company expects to have its first product, targeting bone loss in osteoporosis patients, ready to license to a pharmaceutical company next year. Proceeds from the offer will be used to develop and build a range of antibody products, with existing disease targets including respiratory disease and liver cancer.

The Sydney Morning Herald (http://www.smh.com.au/news/business/evogenix-aims-for-faster-road-to-revenue/2005/07/05/1120329446671.html?oneclick=true)